Lundbeck opens Lexapro plant in UK  

2002.12.10
H Lundbeck A/S has officially opened a EUR 80 million pharmaceutical plant in UK
Danish pharmaceutical manufacturer H Lundbeck A/S has officially opened a EUR 80 million pharmaceutical plant on Teesside in north east England. The new facility will make escitalopram – the active ingredient in Lundbeck's new anti-depressant drug Lexapro/Cipralex – and includes new technology in the form of a large-scale simulated moving bed (SMB) unit, said to the one of the largest in the world. SMB is the core technology that allows separation of the isomeric forms of citalopram and makes production of pure escitalopram possible. Speed to market is critical for the launch of new drug products, and the UK facility has been built to support both the launch and post-launch phase of Lexapro. The news is reported by IPAWorld.com.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×